trial
as of 2026-07-01Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
NCTId NCT01573637
at a glance
Phase 3 · Completed
Enrollment 78 (actual)
Sponsored by Fundació Sant Joan de Déu
Primary completion 2014-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
78 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-07
Primary completion
2014-07
Eligibility
FEMALE · 45 Years
Interventions & indications
Drugs
Sponsors
Fundació Sant Joan de DéuLead Sponsor
Hospital Sant Joan de DeuCollaborator
Parc Sanitari Sant Joan de DéuCollaborator
Stanley Medical Research InstituteCollaborator
Investigators
3
Judith Usall, PhMDPrincipal Investigator
Javier Labad Arias, PhMDPrincipal Investigator
Gemma García-Parés, PhMDPrincipal Investigator
Sites
3 total
Sabadell, SpainSant Boi de Llobregat, SpainReus, Spain
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
78
Phase
PHASE3
Primary Completion Date
2014-07
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
indication
indication
indication
investigator